Skönhetsprodukter med dokumenterad effekt          ✔1- 3 dagars leveranstid          ✔Fri frakt 

Forskning

Collagen Induction Therapy (CIT Roller) research:

A 2006 study showed an average increase of 206% in collagen fibres after a single treatment. The highest increase in collagen induction recorded was 1,000% after a single treatment (1).

In 2008 480 patients with fine wrinkles, lax skin, scarring, and stretch marks rated their improvement as between 60-80% better following micro needling. (13)A 2010 study showed a 140% increase in the thickness of the epidermis and also showed an increase in gene and protein expression of collagen 1, and growth factors such as VEGF and EGF. It also demonstrated an increase in the number of and thickness of the collagen bundles (3)

A small trial in 2010 also showed positive initial results with hand rejuvenation in both skin texture and skin tightening (4)

A 2011 study directly compared micro needling to Intense Pulsed Light (IPL) therapy. The study concluded that micro needling resulted in greater skin thickening and expression of collagen type 1 as well as total collagen content (5).

Reduce scars with micro needling

A 2009 study showed that 34 of 37 people treated with a micro needle roller received a 1 or 2 grade improvements in the appearance of the scars (6).

In 2010 16 patients suffering post burn scars were treated with a micro needle roller and rated their average improvement at 80%.

When the skin was examined 12 months later a large increase in collagen and elastin was found and a 45% thickening of one of the damaged surface levels of the skin (7)

The study confirms that skin needling has an immediate effect in improving acne rolling scars and has advantages over other procedures (12)

Collagen induction Therapy was started in 1997 and has proved to be a simple and fast method for safely treating wrinkles and scars. Alternative treatment for scars, wrinkles, and skin laxity (12)

A 2014 study showed that microneedling is a effective treatment modality for acne scars remodulation with little downtime, satisfactory results and peculiar side effects in Asian skin type. The age group ranged from 18 to 40 years. 50–75% improvement in majority of patients. (13)

Reducing Stretch Marks

In 2010 22 women, suffering stretch marks showed significant increases in both collagen and elastin fibres in the area following treatment with a micro needle roller (8).

In 2008 480 patients with fine wrinkles, lax skin, scarring, and stretch marks rated their improvement as between 60-80% better following micro needling. (13)

Trans-dermal Absorption

It is well know that micro needling dramatically increases the absorption of products applied to the skin.

A study in 1998 showed that this increase can vary between 1000-10,000 times, dramatically increasing the absorption of beauty products through the skin (9).

Safe for Multi-racial Skin

A 2008 study demonstrated that micro needling does not result in the loss of melanocytes. This means there is no risk of dyspigmentation or hyper pigmentation for those with darker skin (10).

A 2014 study showed that microneedling is a effective treatment modality for acne scars remodulation with little downtime, satisfactory results and peculiar side effects in Asian skin type. 50–75% improvement in majority of patients. (13)

References available upon request

 

Menacin Vitamin K2 research:

Dietary intake of vitamin K and risk of prostate cancer in the Heidelberg cohort of the European Prospective Investigsation into cancer and nutrition (EPIC-Heidelberg).

By Nimptsch, K et al. Am J Clin Nutr 2008, 87,985-92

Previous publications have indicated that vitamin K2- seems to have a role in inhibiting certain cancers, notably liver cancer. This may be so because the molecular structure of vitamin K2 resembles the structure of certain chemotherapeutics, and that they may act in similar ways to inhibit cancer cell growth and promote cell death.

The Nimptsch-article describes a very large and well controlled population based study from Germany looking at the relationship of dietary vitamin K2 and prostate cancer during the years 1998 to 2007.

During this period more than 11 000 men are checked three times for their health status and food consumption in relation to the development and occurrence of prostate cancer. After an observation period of 97 731 man-years 268 cases of prostate cancer, including 113 severe cases, are identified. The estimated dietary intake of vitamin K2 is based upon known databases for content of vitamin K2 in food products. The results show that the more vitamin K2 the men consume, the less risk for prostate cancer. It indicated a reduction of up to 60% risk of reduction.

New study indicate that a daily intake of Vitamin K2 significantly reduce the risk of developing or die of cancer

Recent studies have suggested an anticarcinogenic effect of vitamin K2 on prostate cancer of approx 50%, while no effect was found for K1. In a new study from the researchers from the German Cancer Research Centre confirms and even extents this effect: the potential benefits of vitamin K2 accounts for overall-cancer risk in both men and women, whereas vitamin K1 shows no effect.

The findings, based on data from the 24,340 men and women taking part in the prospective EPIC Heidelberg cohort, are published in this month's issue of the American Journal of Clinical Nutrition*. All 24,340 participants (aged 35-64 y) were free of cancer at enrollment and followed up for cancer incidence and mortality. Dietary vitamin K intake was estimated from food-frequency questionnaires. During a 10 year follow-up, 1755 incident cancer cases occurred, of which 458 were fatal. Cancer risk reduction with increasing intake of vitamin K2, mainly the long chain menaquinones such as NattoPharma's MenaQ7 was recorded.

In general, the researchers found, the one quarter with the highest intakes of vitamin K2 were 28% less likely to have died of any one of the 22 different cancers than the one-quarter of men and women with the lowest intakes of the vitamin. Subjects in the highest quartile of vitamin K2 had a 62% reduced risk of lung cancer and lung cancer mortality. For prostate cancer this figure was 42% reduced risk.

"It is at least remarkable that cancer-prevention was found to occur at similar intakes of vitamin K2 as the previously observed protection against cardiovascular disease and mortality. Both for cancer protection and cardiovascular disease prevention a nutritional dose of 45 micrograms per day was found to show a significant effect, although probably more profound effects may even be expected from higher doses" says Cees Vermeer, PhD, Associate Professor of Biochemistry VitaK BV, Maastricht University.

The study has been appreciated by Leon Schurgers, PhD, from the Cardiovascular Research Institute CARIM at the University of Maastricht and vice president of NattoPharma, Oslo, Norway."The anti-carcinogenic effect of K2 vitamins has been suggested in several previous papers. The study of Nimptsch and colleagues confirms and adds significant evidence that especially vitamin K2 have anti-carcinogenic properties. The beauty of this paper is that the effect is found at nutritional doses of vitamin K2" says Schurgers.

SOURCE:

American Journal of Clinical Nutrition, online March 24, 2010.

Reuters Health, March 31. 2010

STUDIES OF CARDIO VASCOLAR AND VITAMIN K2:

A large epidemiological population‐based study published in 2004 ‐ The “Rotterdam study”

with 4473 subjects with no history of Myocardial infarction, over a period of 10 years showed a

significant 50% reduction in Coronary Heart Disease CHD ), mortality and aortic calcification CHD

mortality for those who were in the 45 mcg per day of dietary intake of vitamin K2‐7 in the upper

tertile and 25% reduction in 24 mcg per mid tertile compared to the 12.5 mcg per day lower tertile.

Such dose‐response relationship in a population was impressive for the new role of vitamin K2‐7.

Their findings did not show any correlation between vitamin K1 intakes to the CHD outcome.3

“... A statically significant reduction of cardiovascular diseases and death by 50 %...”

The Gast study published in 2009 with 16 057 participants over 8,1 years confirmed the Rotterdam

study and conclude a 9% reduction in risk of developing CHD for every 10 mcg of natural vitamin K2

consumed. The highest average consumption was >36 mcg K2/day. This study could not confirm a

protective effect of vitamin K1 for coronary calcification and CHD similar to the conclusions of

Rotterdam study. The need for a higher dose of vitamin K2‐7 was obvious.37

“...9 % reduction of risk of Coronary Heart Disease for every 10 mcg natural K2‐7 a day...”

Source: Gast. GCM at al. A high Menaquione reduces the incidence of coronary heart diseases in woman. J Nutr Met &

cardio. 2008

Knappen et al[1](2013) showed that natural vitamin K2 as MK-7 intake significantly improved vitamin K status and decreased the age-related decline in BMC and BMD at the lubar spine and femoral neck, but not at the total hip. Bone strength was also favorable affected by MK-7, and it decreased significantly the loss in vertebral height of the lower thoracic region at the mid-site of the vertebrae. Thus, the conclusion was that MK-7 supplements may help postmenopausal women to prevent bone loss.

They investigated whether low-dose vitamin K2 supplements (menaquinone-7, MK-7) could beneficially affect bone health. Next to an improved vitamin K status, MK-7 supplementation significantly decreased the age-related decline in bone mineral density and bone strength. Low-dose MK-7 supplements may therefore help postmenopausal women prevent bone loss.

Healthy postmenopausal women (n=244) received for 3 years placebo or MK-7 (180 μg MK-7/day) capsules. Bone mineral density of lumbar spine, total hip, and femoral neck was measured by DXA; bone strength indices of the femoral neck were calculated. Vertebral fracture assessment was performed by DXA and used as measure for vertebral fractures. Circulating uncarboxylated osteocalcin (ucOC) and carboxylated OC (cOC) were measured; the ucOC/cOC ratio served as marker of vitamin K status. Measurements occurred at baseline and after 1, 2, and 3 years of treatment.

MK-7 intake significantly improved vitamin K status and decreased the age-related decline in BMC and BMD at the lumbar spine and femoral neck, but not at the total hip. Bone strength was also favorably affected by MK-7. MK-7 significantly decreased the loss in vertebral height of the lower thoracic region at the mid-site of the vertebrae.

MK-7 supplements may help postmenopausal women to prevent bone loss. Whether these results can be extrapolated to other populations, e.g., children and men, needs further investigation.

M. H. J. Knapen & N. E. Drummen & E. Smit & C. Vermeer & E. Theuwissen (2013). “Three-year low-dose menaquinone-supplementation helps decrease bone loss in healthy postmenopausal women” Osteoporos Int DOI 10.1007/s00198-013-2325-6.

[1]Lukacs JL, Booth S, Kleerekoper M, Ansbacher R, Rock CL, Reame NE: Differential associations for menopause and age in measures of vitamin K, osteocalcin, and bone density: a cross-sectional exploratory study in healthy volunteers. Menopause 2006, 13(5):799-808